Orrin M. Troum, MD

Articles by Orrin M. Troum, MD

The Expanding Arsenal in Systemic Autoimmune Disease in 2025 and Beyond, With Orrin Troum, MD, and Alvin Wells, MD, PhD

ByOrrin M. Troum, MD,Alvin Wells, MD, PhD

March 9th 2026

Wells and Troum discussed advances in 2025 that are continuing to transform the systemic autoimmune diseases.

Integrating AI Into Everyday Rheumatology Practice, with Alvin Wells, MD, PhD, and Orrin Troum, MD

ByOrrin M. Troum, MD,Alvin Wells, MD, PhD

February 24th 2026

Troum and Wells discussed how AI tools help clinicians in their practice.

Orrin Troum, MD, clinical professor of medicine, Keck School of Medicine, University of Southern California, and director, clinical rheumatology research, Providence St John's Hospital, Santa Monica, California

Phase 4 Studies Support Alternative Pegloticase Dosing Regimens for Uncontrolled Gout, with Orrin Troum, MD

ByOrrin M. Troum, MD

July 17th 2025

The AGILE and FORWARD studies found comparable efficacy and safety with shorter doses and higher dose, monthly doses, compared to the pivotal MIRROR trial.

Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning

ByOrrin M. Troum, MD,Victoria Johnson

December 4th 2024

Troum discussed the AGILE study and how DECT scanning helped visualize improvements in uncontrolled gout.

Latest Updated Articles

Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
December 4th 2024
Phase 4 Studies Support Alternative Pegloticase Dosing Regimens for Uncontrolled Gout, with Orrin Troum, MD
July 17th 2025

Orrin M. Troum, MD

Articles by Orrin M. Troum, MD

The Expanding Arsenal in Systemic Autoimmune Disease in 2025 and Beyond, With Orrin Troum, MD, and Alvin Wells, MD, PhD

Integrating AI Into Everyday Rheumatology Practice, with Alvin Wells, MD, PhD, and Orrin Troum, MD

Phase 4 Studies Support Alternative Pegloticase Dosing Regimens for Uncontrolled Gout, with Orrin Troum, MD

Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning

Latest Updated Articles

Trending on Rheumatology Live

Belimumab Nearly Doubled Non-GC Remission and LLDAS Rates in SLE Post-Hocs

Risankizumab’s Durable Efficacy, Safety in PsA, With Frank Behrens, MD

Allocetra Immunotherapy Gets RMAT Designation for Age-Related Knee Osteoarthritis